Literature DB >> 17912043

Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.

Amy J Tallett1, John E Blundell, John R Rodgers.   

Abstract

Despite a large and consistent literature on the suppressant effects of cannabinoid CB1 receptor antagonists/inverse agonists (e.g. rimonabant, AM 251) on food intake and weight gain in rodents, surprisingly little is known about the behavioural selectivity of such effects. In this study, ethological scoring was used to characterize the acute behavioural effects of the rimonabant analogue AM 251 (1.5 and 3.0 mg/kg, intraperitoneally) in nondeprived male rats during a 1-h test with palatable mash. Data were also collected on daily weight gain and on retest food intake 7 days after dosing. Results showed that the higher dose of AM 251 significantly inhibited mash consumption (32% decrease relative to vehicle control), reduced time spent feeding during the test and suppressed body weight gain over the 48-h period that followed acute dosing. No effects on mash consumption were observed when the animals were retested drug-free 1 week after drug treatment. Detailed video analysis of the test sessions showed that, over the dose range tested, AM 251 did not significantly interfere with the vast majority of noningestive behaviours. Both doses of the compound, however, significantly increased the incidence of and the time spent on scratching, whereas the higher dose additionally increased both the number and duration of grooming episodes. The latter effect in particular disrupted the normal structure of behaviour (behavioural satiety sequence) with atypically high levels of grooming displacing feeding during the middle part of the test session. Overall, the behavioural profile of AM 251 in a free-feeding context is very similar to (but approximately two-fold less potent than) that recently reported for the parent molecule, rimonabant. Together, these data strongly suggest that the acute anorectic response to CB1 receptor antagonists/inverse agonists is indirectly mediated via major alterations to other components of the behavioural repertoire.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912043     DOI: 10.1097/FBP.0b013e3282eff0a9

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  13 in total

1.  The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.

Authors:  Garron T Dodd; Giacomo Mancini; Beat Lutz; Simon M Luckman
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats.

Authors:  Janel Hodge; Joshua P Bow; Kimberly S Plyler; V Kiran Vemuri; Ania Wisniecki; John D Salamone; Alexandros Makriyannis; Peter J McLaughlin
Journal:  Behav Brain Res       Date:  2008-06-17       Impact factor: 3.332

3.  Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2012-11-10       Impact factor: 4.530

4.  The CB1 cannabinoid receptor mediates glucocorticoid-induced effects on behavioural and neuronal responses during lactation.

Authors:  Fabiana Cardoso Vilela; Silvia Graciela Ruginsk; Carla Martins de Melo; Alexandre Giusti-Paiva
Journal:  Pflugers Arch       Date:  2013-02-17       Impact factor: 3.657

5.  Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists.

Authors:  P J McLaughlin; K M Winston; L A Swezey; V K Vemuri; A Makriyannis; J D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2010-04-18       Impact factor: 3.533

6.  Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys.

Authors:  Charles W Schindler; Leigh V Panlilio; Joanne P Gilman; Zuzana Justinova; V Kiran Vemuri; Alex Makriyannis; Steven R Goldberg
Journal:  Eur J Pharmacol       Date:  2010-02-11       Impact factor: 4.432

7.  Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.

Authors:  K S Sink; K N Segovia; J Sink; P A Randall; L E Collins; M Correa; E J Markus; V K Vemuri; A Makriyannis; J D Salamone
Journal:  Eur Neuropsychopharmacol       Date:  2009-12-16       Impact factor: 4.600

8.  Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.

Authors:  Joyonna C Gamble-George; Jordan R Conger; Nolan D Hartley; Prerna Gupta; Joshua J Sumislawski; Sachin Patel
Journal:  Psychopharmacology (Berl)       Date:  2013-03-13       Impact factor: 4.530

9.  Cannabinoid receptor 1 disturbance of PPARγ2 augments hyperglycemia induction of mesangial inflammation and fibrosis in renal glomeruli.

Authors:  Chun-Liang Lin; Yung-Chien Hsu; Pei-Hsien Lee; Chen-Chou Lei; Jeng-Yi Wang; Yu-Ting Huang; Shao-Yu Wang; Feng-Sheng Wang
Journal:  J Mol Med (Berl)       Date:  2014-04-11       Impact factor: 4.599

10.  Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.

Authors:  T U C Järbe; B J LeMay; T Olszewska; V K Vemuri; J T Wood; A Makriyannis
Journal:  Pharmacol Biochem Behav       Date:  2008-06-29       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.